Skip to content

Mazdutide vs Survodutide

Updated 8 sources

Key differences

  1. 1Same two targets, GLP-1 and glucagon. Mazdutide is built on oxyntomodulin; survodutide is built on glucagon.
  2. 2Mazdutide is approved in China as Xinermei. Survodutide is approved nowhere.
  3. 3Mazdutide's phase 3 data come mostly from Chinese adults; survodutide's come from multinational trials.
  4. 4Same two targets, GLP-1 and glucagon. Survodutide is built on glucagon; mazdutide is built on oxyntomodulin.
  5. 5Survodutide's phase 3 data come from multinational trials; mazdutide's come mostly from Chinese adults.

Side by side

Facts from each record, in the same words as their own pages.
Mazdutide and Survodutide side by side
MazdutideSurvodutide
Category
  • GLP-1, Weight loss
  • GLP-1, Weight loss
Evidence
  • Strong human trials
  • Strong human trials
FDA status
  • In clinical trialsRegulatory
  • In clinical trialsRegulatory
WADA
  • Not prohibited
  • Not confirmed
Half-life
  • 6.3 to 16.8 days after the first dose in a phase 1b trial in Chinese adults; peak levels at a median of 72 hours.Clinical study
  • About 6 to 7 days, an estimate from one guide. We found no published human half-life figure.Competitor guide
Routes
  • Subcutaneous injection
  • Subcutaneous injection
Forms
  • Prefilled pen, Vial (powder)
  • Vial (powder), Other form
Reported doses
  • 1 to 16 mg (subcutaneous injection)
  • 0.3 to 6 mg (subcutaneous injection)
Most cited frequency
  • Once weekly: 2 mg for 4 weeks, 4 mg for 4 weeks, then 4 or 6 mg to maintain
  • Once weekly, stepped up to a target of 3.6 or 6.0 mg, then held to week 76
Vial sizes
  • 5 mg, 10 mg, 15 mg, 20 mgCompetitor guide
  • 5 mg, 6 mg, 10 mg, 20 mgCompetitor guide
Mixed vial keeps
  • Keep the mixed vial in the fridge at 2 to 8 C and never freeze it.Competitor guide
  • Keep the mixed vial in the fridge at 2 to 8 C, away from light, and do not freeze and thaw it.Competitor guide
Protocols on file
  • 13
  • 10

Doses shown are what sources report, labelled by origin. Not medical advice.

Read each in full

Sources

8 sources, each checked by date. Record updated Oct 24, 2026. Numbers are restated in our own words and labelled by where they came from.

Regulatory4

  1. Mazdutide: First ApprovalDrugs (PubMed record), via a reference work · checked Oct 24, 2026
  2. Innovent Announces Mazdutide Received Approval from China's NMPA for Glycemic Control in Adults with Type 2 DiabetesInnovent Biologics (via BioSpace), via a news report · checked Oct 24, 2026
  3. Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutideBoehringer Ingelheim (via BioSpace), via a news report · checked Oct 24, 2026
  4. WADA 2026 Prohibited ListWADA · checked Oct 24, 2026

Reference work2

  1. SurvodutideWikipedia · checked Oct 24, 2026
  2. MazdutideWikipedia · checked Oct 24, 2026

Competitor guide1

  1. Survodutide dosingPeptide Protocol Wiki · checked Oct 24, 2026